Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
36
UNCY Quote, Financials, Valuation and Earnings
Last price:
$5.57
Seasonality move
:
72.91%
Day range:
$5.37 - $5.58
52-week range:
$3.71 - $11.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.19x
Volume:
390.1K
Avg. volume:
419.2K
1-year change:
-21.69%
Market cap:
$119.5M
Revenue:
--
EPS (TTM):
-$2.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UNCY
Unicycive Therapeutics, Inc.
|
$14.3M | $0.14 | -100% | -76.86% | $46.52 |
|
AVTR
Avantor, Inc.
|
$1.6B | $0.20 | -2.99% | -70.55% | $13.32 |
|
CATX
Perspective Therapeutics, Inc.
|
$147K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$17.8M | -- | 11.04% | -- | $36.00 |
|
TMCI
Treace Medical Concepts, Inc.
|
$52M | -$0.24 | -10.11% | -1650% | $5.27 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$28.5M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UNCY
Unicycive Therapeutics, Inc.
|
$5.56 | $46.52 | $119.5M | -- | $0.00 | 0% | -- |
|
AVTR
Avantor, Inc.
|
$11.27 | $13.32 | $7.7B | 10.97x | $0.00 | 0% | 1.17x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7500 | $12.3077 | $204.4M | -- | $0.00 | 0% | 186.46x |
|
ELMD
Electromed, Inc.
|
$28.62 | $36.00 | $238.7M | 30.79x | $0.00 | 0% | 3.82x |
|
TMCI
Treace Medical Concepts, Inc.
|
$2.57 | $5.27 | $163.8M | -- | $0.00 | 0% | 0.74x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.77 | $1.50 | $107.8M | 75.49x | $0.00 | 0% | 0.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UNCY
Unicycive Therapeutics, Inc.
|
0.7% | -2.205 | 0.29% | 3.25x |
|
AVTR
Avantor, Inc.
|
40.92% | 0.979 | 45.33% | 0.90x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.217 | -- | 4.58x |
|
TMCI
Treace Medical Concepts, Inc.
|
44.1% | 1.305 | 16.46% | 2.25x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UNCY
Unicycive Therapeutics, Inc.
|
-$148K | -$7.3M | -162.08% | -166.6% | -- | -$6M |
|
AVTR
Avantor, Inc.
|
$526.5M | $138.4M | -0.81% | -1.4% | 8.52% | $171.7M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
TMCI
Treace Medical Concepts, Inc.
|
$39.7M | -$15.7M | -29.15% | -49.13% | -31.22% | -$11.9M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Unicycive Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns UNCY or AVTR?
Avantor, Inc. has a net margin of -- compared to Unicycive Therapeutics, Inc.'s net margin of -43.84%. Unicycive Therapeutics, Inc.'s return on equity of -166.6% beat Avantor, Inc.'s return on equity of -1.4%.
Company Gross Margin Earnings Per Share Invested Capital UNCYUnicycive Therapeutics, Inc.-- -$0.33 $37.7M AVTRAvantor, Inc.32.42% -$1.04 $9.4B -
What do Analysts Say About UNCY or AVTR?
Unicycive Therapeutics, Inc. has a consensus price target of $46.52, signalling upside risk potential of 736.76%. On the other hand Avantor, Inc. has an analysts' consensus of $13.32 which suggests that it could grow by 18.2%. Given that Unicycive Therapeutics, Inc. has higher upside potential than Avantor, Inc., analysts believe Unicycive Therapeutics, Inc. is more attractive than Avantor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UNCYUnicycive Therapeutics, Inc.6 0 0 AVTRAvantor, Inc.4 13 1 -
Is UNCY or AVTR More Risky?
Unicycive Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.02%.
-
Which is a Better Dividend Stock UNCY or AVTR?
Unicycive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unicycive Therapeutics, Inc. pays 2.98% of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend. Unicycive Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UNCY or AVTR?
Unicycive Therapeutics, Inc. quarterly revenues are --, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Unicycive Therapeutics, Inc.'s net income of -$6M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Unicycive Therapeutics, Inc.'s price-to-earnings ratio is -- while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unicycive Therapeutics, Inc. is -- versus 1.17x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UNCYUnicycive Therapeutics, Inc.-- -- -- -$6M AVTRAvantor, Inc.1.17x 10.97x $1.6B -$711.8M
-
Which has Higher Returns UNCY or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to Unicycive Therapeutics, Inc.'s net margin of -12425.36%. Unicycive Therapeutics, Inc.'s return on equity of -166.6% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital UNCYUnicycive Therapeutics, Inc.-- -$0.33 $37.7M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About UNCY or CATX?
Unicycive Therapeutics, Inc. has a consensus price target of $46.52, signalling upside risk potential of 736.76%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 347.55%. Given that Unicycive Therapeutics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Unicycive Therapeutics, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UNCYUnicycive Therapeutics, Inc.6 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is UNCY or CATX More Risky?
Unicycive Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock UNCY or CATX?
Unicycive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unicycive Therapeutics, Inc. pays 2.98% of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend. Unicycive Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UNCY or CATX?
Unicycive Therapeutics, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Unicycive Therapeutics, Inc.'s net income of -$6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Unicycive Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unicycive Therapeutics, Inc. is -- versus 186.46x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UNCYUnicycive Therapeutics, Inc.-- -- -- -$6M CATXPerspective Therapeutics, Inc.186.46x -- $209K -$26M
-
Which has Higher Returns UNCY or ELMD?
Electromed, Inc. has a net margin of -- compared to Unicycive Therapeutics, Inc.'s net margin of 12.65%. Unicycive Therapeutics, Inc.'s return on equity of -166.6% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital UNCYUnicycive Therapeutics, Inc.-- -$0.33 $37.7M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About UNCY or ELMD?
Unicycive Therapeutics, Inc. has a consensus price target of $46.52, signalling upside risk potential of 736.76%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.79%. Given that Unicycive Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Unicycive Therapeutics, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UNCYUnicycive Therapeutics, Inc.6 0 0 ELMDElectromed, Inc.4 0 0 -
Is UNCY or ELMD More Risky?
Unicycive Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.
-
Which is a Better Dividend Stock UNCY or ELMD?
Unicycive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unicycive Therapeutics, Inc. pays 2.98% of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend. Unicycive Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UNCY or ELMD?
Unicycive Therapeutics, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Unicycive Therapeutics, Inc.'s net income of -$6M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Unicycive Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unicycive Therapeutics, Inc. is -- versus 3.82x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UNCYUnicycive Therapeutics, Inc.-- -- -- -$6M ELMDElectromed, Inc.3.82x 30.79x $16.9M $2.1M
-
Which has Higher Returns UNCY or TMCI?
Treace Medical Concepts, Inc. has a net margin of -- compared to Unicycive Therapeutics, Inc.'s net margin of -32.44%. Unicycive Therapeutics, Inc.'s return on equity of -166.6% beat Treace Medical Concepts, Inc.'s return on equity of -49.13%.
Company Gross Margin Earnings Per Share Invested Capital UNCYUnicycive Therapeutics, Inc.-- -$0.33 $37.7M TMCITreace Medical Concepts, Inc.79.07% -$0.26 $159.6M -
What do Analysts Say About UNCY or TMCI?
Unicycive Therapeutics, Inc. has a consensus price target of $46.52, signalling upside risk potential of 736.76%. On the other hand Treace Medical Concepts, Inc. has an analysts' consensus of $5.27 which suggests that it could grow by 105.06%. Given that Unicycive Therapeutics, Inc. has higher upside potential than Treace Medical Concepts, Inc., analysts believe Unicycive Therapeutics, Inc. is more attractive than Treace Medical Concepts, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UNCYUnicycive Therapeutics, Inc.6 0 0 TMCITreace Medical Concepts, Inc.1 4 0 -
Is UNCY or TMCI More Risky?
Unicycive Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Treace Medical Concepts, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock UNCY or TMCI?
Unicycive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unicycive Therapeutics, Inc. pays 2.98% of its earnings as a dividend. Treace Medical Concepts, Inc. pays out -- of its earnings as a dividend. Unicycive Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UNCY or TMCI?
Unicycive Therapeutics, Inc. quarterly revenues are --, which are smaller than Treace Medical Concepts, Inc. quarterly revenues of $50.2M. Unicycive Therapeutics, Inc.'s net income of -$6M is higher than Treace Medical Concepts, Inc.'s net income of -$16.3M. Notably, Unicycive Therapeutics, Inc.'s price-to-earnings ratio is -- while Treace Medical Concepts, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unicycive Therapeutics, Inc. is -- versus 0.74x for Treace Medical Concepts, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UNCYUnicycive Therapeutics, Inc.-- -- -- -$6M TMCITreace Medical Concepts, Inc.0.74x -- $50.2M -$16.3M
-
Which has Higher Returns UNCY or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -- compared to Unicycive Therapeutics, Inc.'s net margin of 3.93%. Unicycive Therapeutics, Inc.'s return on equity of -166.6% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital UNCYUnicycive Therapeutics, Inc.-- -$0.33 $37.7M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About UNCY or XTNT?
Unicycive Therapeutics, Inc. has a consensus price target of $46.52, signalling upside risk potential of 736.76%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 94.81%. Given that Unicycive Therapeutics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Unicycive Therapeutics, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UNCYUnicycive Therapeutics, Inc.6 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is UNCY or XTNT More Risky?
Unicycive Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock UNCY or XTNT?
Unicycive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Unicycive Therapeutics, Inc. pays 2.98% of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend. Unicycive Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UNCY or XTNT?
Unicycive Therapeutics, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Unicycive Therapeutics, Inc.'s net income of -$6M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Unicycive Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 75.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Unicycive Therapeutics, Inc. is -- versus 0.84x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UNCYUnicycive Therapeutics, Inc.-- -- -- -$6M XTNTXtant Medical Holdings, Inc.0.84x 75.49x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
